BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 19891683)

  • 1. An evidence-based approach to anaemia management in predialysis chronic kidney disease.
    Pugh-Clarke K; Cooper L; Turner J; Fermin J
    J Ren Care; 2009 Dec; 35 Suppl 2():29-31. PubMed ID: 19891683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients.
    Tagboto S; Cropper L; Turner J; Pugh-Clarke K
    J Ren Care; 2009 Mar; 35(1):18-23. PubMed ID: 19200274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic.
    Wilson PD; Hutchings A; Jeans A; Macdougall IC
    J Med Econ; 2013; 16(1):108-14. PubMed ID: 22989163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of iv iron compounds over the last century.
    Macdougall IC
    J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron therapy in chronic kidney disease: current controversies.
    Kovesdy CP; Kalantar-Zadeh K
    J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creative iron management--a practical guide.
    Jenkins K
    J Ren Care; 2009 Dec; 35 Suppl 2():32-5. PubMed ID: 19891684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
    Yong K; Kairaitis L
    Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis.
    Riccio E; Sabbatini M; Capuano I; Pellegrino AM; Petruzzelli LA; Pisani A
    BMC Nephrol; 2020 Feb; 21(1):57. PubMed ID: 32087684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
    Goldstein SL; Morris D; Warady BA
    Am J Kidney Dis; 2013 Apr; 61(4):588-97. PubMed ID: 23245582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron status and benefit of the use of parenteral iron therapy in pre-dialysis Chronic Kidney disease patients.
    Arogundade FA; Soyinka FO; Sanusi AA; Ojo OE; Akinsola A
    Niger Postgrad Med J; 2013 Dec; 20(4):299-304. PubMed ID: 24633272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
    Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parenteral iron sucrose in iron deficiency anaemia of paediatric chronic kidney disease.
    Moorani KN; Asim S
    J Ayub Med Coll Abbottabad; 2011; 23(3):47-50. PubMed ID: 23272434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of iron deficiency in predialysis state by low molecular weight iron dextran high doses intravenously].
    Fievet P; Coppin M; Brazier F; Lefèvre M; Stephan R; Demontis R
    Nephrol Ther; 2012 Feb; 8(1):41-6. PubMed ID: 21684231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lost without directions: lessons from the anemia debate and the drive study.
    Spiegel DM; Chertow GM
    Clin J Am Soc Nephrol; 2009 May; 4(5):1009-10. PubMed ID: 19357246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?
    Badve SV; Hawley CM; Johnson DW
    Nephrology (Carlton); 2011 Feb; 16(2):144-53. PubMed ID: 21272125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.